Fuzhou Meidashan Biotechnology, a Shineco Subsidiary, Achieves Breakthrough in High-Purity Phospholipid Production

Reuters
09/10
Fuzhou Meidashan Biotechnology, a Shineco Subsidiary, Achieves Breakthrough in High-Purity Phospholipid Production

Shineco Inc. has announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has achieved mass production of high-purity, highly active free-form soybean phospholipids. Using its proprietary APCC-UF pure physical extraction technology, this breakthrough addresses a global technical challenge and positions Shineco to compete in markets such as pharmaceutical intermediates and lipid materials for mRNA vaccines. This advancement is expected to significantly impact the global active phospholipid industry and expand applications in pharmaceuticals and high-value health sectors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shineco Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN70107) on September 10, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10